# Three Immunosuppressive Treatment Regimens for Severe Aplastic Anemia

> **NCT00260689** · PHASE2 · COMPLETED · sponsor: **National Heart, Lung, and Blood Institute (NHLBI)** · enrollment: 136 (actual)

## Conditions studied

- Immunosuppresion
- Thrombocytopenia
- Pancytopenia
- Neutropenia

## Interventions

- **BIOLOGICAL:** Anti-thymocyte globulin (rabbit)
- **BIOLOGICAL:** Anti-thymocyte globulin (horse)
- **DRUG:** Cyclosporine
- **DRUG:** Alemtuzumab

## Key facts

- **NCT ID:** NCT00260689
- **Lead sponsor:** National Heart, Lung, and Blood Institute (NHLBI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-11-28
- **Primary completion:** 2016-05-04
- **Final completion:** 2016-05-04
- **Target enrollment:** 136 (ACTUAL)
- **Last updated:** 2017-06-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00260689

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00260689, "Three Immunosuppressive Treatment Regimens for Severe Aplastic Anemia". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00260689. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*